New Diabetes Study by Cutting Edge Information Examines Drugs, Classes, and Market Leaders

RESEARCH TRIANGLE PARK, NC--(Marketwire - January 6, 2010) - Cutting Edge Information (CEI) announces the release of its newest diabetes market forecast study. (

Since 2008, Cutting Edge Information has developed forecasting data for the diabetes treatment market. The new report -- "Diabetes Market Forecast to 2015" -- provides a deep analysis of the relevant clinical, commercial, and market trends affecting diabetes therapeutics today and their impact leading into the next decade. In addition to detailed drug, class, and company profiles, the study includes primary research findings generated from survey data and interviews with leading physicians and marketing executives.

The study also details the historical, current and forecasted performance of 45 drugs treating Type 1 and Type 2 diabetes and their associated complications. Included are marketed brands and pipeline products in clinical development and analysis of the top 10 drug makers in the diabetes area. The report's structure leads to data comparisons and analysis across multiple levels.

A complimentary report brochure is available for download at

The report's expanded content uncovers physician and industry perspectives on the current direction of diabetes research, most effective marketed therapies -- as well as novel treatments in development -- and unmet needs across various regions in the global diabetes market. Special attention is given to companies' responses to the FDA's new cardiovascular guidelines.

"The diabetes market is expected to see incredible growth in the near future, at about 70 percent by 2015," said Shaylyn Pike, lead author of the report. "Our study points out key areas of opportunity for pharma companies, as well as research areas to avoid -- information especially helpful as me-too drugs continue to fall out of favor."

The report is organized into profiles for individual brands and drug manufacturers.

Brand Profiles detail a product's competitive and strategic positioning, market opportunities, and patent and litigation data. Profiles include the following information:

--  Drug's current and projected competitive strength
--  Current/projected sales position within its class
--  Sales projection charts through 2015
--  Assessment of competition 
--  Materiality charts
--  Clinical trial information
--  Patent expirations

Company Profiles show breakdowns for 10 companies that have established antidiabetes franchises or exciting development pipelines. Profiles contain:

--  Diabetes market position/ranking
--  Market forecast
--  Strengths analysis
--  Growth areas analysis
--  Market-changing opportunities analysis
--  Key products breakdown

Contact Information: CONTACT INFORMATION: Stephanie Swanson 919-433-0212